Trials / Completed
CompletedNCT00893464
A Study of IXAZOMIB in Adult Patients With Lymphoma
An Open-Label, Dose-Escalation, Phase 1 Study of IXAZOMIB (MLN9708), A Second-Generation Proteasome Inhibitor, in Adult Patients With Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Millennium Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open-label, multicenter, phase 1, dose-escalation study of IXAZOMIB in adult patients with lymphoma. This study will be the first to administer IXAZOMIB to patients with lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IXAZOMIB | Patients will be administered IXAZOMIB by IV on Days 1, 8, and 15 of a 28-day cycle. The first stage of the study will be initiated at a starting dose of 0.125 mg/m2. Subsequent doses will increase until a maximum tolerated dose (MTD) is established. |
Timeline
- Start date
- 2009-08-01
- Primary completion
- 2014-10-01
- Completion
- 2014-10-01
- First posted
- 2009-05-06
- Last updated
- 2015-11-11
- Results posted
- 2015-11-11
Locations
7 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00893464. Inclusion in this directory is not an endorsement.